Morgan Stanley’s Ocera Therapeutics, Inc. OCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-4,456
| Closed | -$6K | – | 6816 |
|
|
2017
Q3 | $6K | Sell |
4,456
-14,910
| -77% | -$16K | ﹤0.01% | 6272 |
|
|
2017
Q2 | $23K | Sell |
19,366
-7,798
| -29% | -$9.06K | ﹤0.01% | 6055 |
|
|
2017
Q1 | $36K | Buy |
27,164
+24,876
| +1,087% | +$31.7K | ﹤0.01% | 5928 |
|
|
2016
Q4 | $5K | Buy |
2,288
+971
| +74% | +$2.27K | ﹤0.01% | 6284 |
|
|
2016
Q3 | $3K | Hold |
1,317
| – | – | ﹤0.01% | 6343 |
|
|
2016
Q2 | $3K | Hold |
1,317
| – | – | ﹤0.01% | 6335 |
|
|
2016
Q1 | $4K | Buy |
+1,317
| New | +$3.76K | ﹤0.01% | 6342 |
|
|
2015
Q3 | – | Sell |
-7,028
| Closed | -$27K | – | 6843 |
|
|
2015
Q2 | $27K | Buy |
7,028
+6,995
| +21,197% | +$26.8K | ﹤0.01% | 6058 |
|
|
2015
Q1 | $0 | Sell |
33
-3,515
| -99% | -$20.3K | ﹤0.01% | 6758 |
|
|
2014
Q4 | $23K | Buy |
+3,548
| New | +$20.8K | ﹤0.01% | 6017 |
|
|
2014
Q3 | – | Sell |
-18,309
| Closed | -$140K | – | 6750 |
|
|
2014
Q2 | $140K | Buy |
18,309
+17,150
| +1,480% | +$137K | ﹤0.01% | 5334 |
|
|
2014
Q1 | $12K | Sell |
1,159
-10,727
| -90% | -$153K | ﹤0.01% | 6092 |
|
|
2013
Q4 | $154K | Buy |
+11,886
| New | +$111K | ﹤0.01% | 5151 |
|
Morgan Stanley's OCRX Position: Q4 2017 in Review
Morgan Stanley sold out of Ocera Therapeutics, Inc. (OCRX) in Q4 2017, closing a stake of 4,456 shares — an estimated $6K sold.
Morgan Stanley first reported a position in OCRX in Q4 2013 and held it in 13 quarters. The position peaked at $154K in Q4 2013. 0 funds tracked by Wall St. Rank hold OCRX as of Q4 2017.
- Morgan Stanley reported no remaining Ocera Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
- Morgan Stanley sold 4,456 Ocera Therapeutics, Inc. shares in Q4 2017, an estimated $6K.
- Morgan Stanley first reported a position in Ocera Therapeutics, Inc. in Q4 2013 and held it in 13 quarters.
- Morgan Stanley's Ocera Therapeutics, Inc. position peaked at $154K in Q4 2013.
- 0 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q4 2017.
Based on Morgan Stanley's 13F filing for Q4 2017, filed 14 Feb 2018.